# EDGAR Filing Document

**Accession Number:** 0001505497
**File Stem:** 0001567619-23-003891
**Filing Date:** 2023-2
**Character Count:** 7923
**Document Hash:** ddc34e301eddf26be81e2c0ee62ea1b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001567619-23-003891.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001567619-23-003891

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230218

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Silva Francisco
- **CENTRAL INDEX KEY:** 0001527241

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37603
- **FILM NUMBER:** 23678368

**MAIL ADDRESS:**
- **STREET 1:** STEM CELL ASSURANCE, INC.
- **STREET 2:** 555 HERITAGE DRIVE
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33458
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioRestorative Therapies, Inc.
- **CENTRAL INDEX KEY:** 0001505497
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 911835664
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747
- **BUSINESS PHONE:** (631) 760-8100

**MAIL ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stem Cell Assurance, Inc.
- **DATE OF NAME CHANGE:** 20101110

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Silva Francisco<br><sub>(Last) (First) (Middle)</sub><br>40 MARCUS DRIVE<br><sub>(Street)</sub><br>MELVILLE, NY 11747<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_VP of Research and Development_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BioRestorative Therapies, Inc. [ BRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-18 |  | F<sup>(1)</sup> |  | 374 | D | $2.99 | 165672<sup>(2)</sup> | D |  |
| Common Stock |  |  |  |  |  |  |  | 12136 | I | IRA |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | 3000. |  |  |  |  |  |  | <sup>(3)</sup> | 2023-10-04 | Common Stock | 1 |  | 1 | D |  |
| Stock Option | 3000. |  |  |  |  |  |  | <sup>(3)</sup> | 2024-02-18 | Common Stock | 3 |  | 3 | D |  |
| Stock Option | $3000 |  |  |  |  |  |  | 2014-03-12 | 2024-03-11 | Common Stock | 1 |  | 1 | D |  |
| Stock Option | $3000 |  |  |  |  |  |  | <sup>(3)</sup> | 2024-10-23 | Common Stock | 9 |  | 9 | D |  |
| Stock Option | $3000 |  |  |  |  |  |  | <sup>(3)</sup> | 2025-09-04 | Common Stock | 6 |  | 6 | D |  |
| Stock Option | $3000 |  |  |  |  |  |  | <sup>(3)</sup> | 2026-06-10 | Common Stock | 15 |  | 15 | D |  |
| Stock Option | $3000 |  |  |  |  |  |  | <sup>(3)</sup> | 2027-07-12 | Common Stock | 20 |  | 20 | D |  |
| Stock Option | $3000 |  |  |  |  |  |  | <sup>(3)</sup> | 2028-10-29 | Common Stock | 25 |  | 25 | D |  |
| Stock Option | $5.08 |  |  |  |  |  |  | <sup>(4)</sup> | 2031-03-18 | Common Stock | 293479 |  | 293479 | D |  |
| Stock Option | $5.08 |  |  |  |  |  |  | <sup>(5)</sup> | 2031-11-04 | Common Stock | 42059 |  | 42059 | D |  |
| Stock Option | $2.91 |  |  |  |  |  |  | <sup>(6)</sup> | 2033-02-17 | Common Stock | 106762 |  | 106762 | D |  |

---

### Footnotes:

(1) Shares were withheld from vested stock grant to pay the associated withholding taxes.

(2) Includes 98,862 shares received pursuant to an unvested restricted stock unit grant.  Such shares vest to the extent of 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.

(3) The option is currently exercisable.

(4) The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.

(5) The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

(6) The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.

**Signature:** /s/ Francisco Silva  
**Date:** 2023-02-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**